HK1099016A1 - Novel compounds as opioid receptor modulators - Google Patents

Novel compounds as opioid receptor modulators

Info

Publication number
HK1099016A1
HK1099016A1 HK07105593.3A HK07105593A HK1099016A1 HK 1099016 A1 HK1099016 A1 HK 1099016A1 HK 07105593 A HK07105593 A HK 07105593A HK 1099016 A1 HK1099016 A1 HK 1099016A1
Authority
HK
Hong Kong
Prior art keywords
opioid receptor
receptor modulators
novel compounds
synthesis
directed
Prior art date
Application number
HK07105593.3A
Other languages
English (en)
Inventor
Henry J Breslin
Chaozhong Cai
Wei He
Robert W Kavash
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1099016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1099016A1 publication Critical patent/HK1099016A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Eye Examination Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Amplitude Modulation (AREA)
  • Hydrogenated Pyridines (AREA)
HK07105593.3A 2004-03-15 2007-05-28 Novel compounds as opioid receptor modulators HK1099016A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15
PCT/US2005/008339 WO2005090315A1 (en) 2004-03-15 2005-03-14 Novel compounds as opioid receptor modulators

Publications (1)

Publication Number Publication Date
HK1099016A1 true HK1099016A1 (en) 2007-08-03

Family

ID=34962827

Family Applications (4)

Application Number Title Priority Date Filing Date
HK07105593.3A HK1099016A1 (en) 2004-03-15 2007-05-28 Novel compounds as opioid receptor modulators
HK07111210.4A HK1105967A1 (en) 2004-03-15 2007-10-17 Novel compounds as opioid receptor modulators
HK11109830.2A HK1155726A1 (en) 2004-03-15 2011-09-19 Opioid receptor modulators
HK13111031.3A HK1184432A1 (en) 2004-03-15 2013-09-27 Process for preparing intermediates of compounds useful as opioid receptor modulators

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK07111210.4A HK1105967A1 (en) 2004-03-15 2007-10-17 Novel compounds as opioid receptor modulators
HK11109830.2A HK1155726A1 (en) 2004-03-15 2011-09-19 Opioid receptor modulators
HK13111031.3A HK1184432A1 (en) 2004-03-15 2013-09-27 Process for preparing intermediates of compounds useful as opioid receptor modulators

Country Status (36)

Country Link
US (8) US7741356B2 (xx)
EP (5) EP2573068B9 (xx)
JP (1) JP4778954B2 (xx)
KR (1) KR101166342B1 (xx)
CN (2) CN1950342B (xx)
AR (2) AR048269A1 (xx)
AT (1) ATE516274T1 (xx)
AU (1) AU2005224091B2 (xx)
BR (1) BRPI0508820B8 (xx)
CA (1) CA2560047C (xx)
CR (1) CR8655A (xx)
CY (3) CY1111927T1 (xx)
DK (5) DK2653465T3 (xx)
EC (1) ECSP066856A (xx)
ES (5) ES2705077T3 (xx)
HK (4) HK1099016A1 (xx)
HR (4) HRP20110694T1 (xx)
HU (2) HUE029852T2 (xx)
IL (3) IL178040A (xx)
LT (2) LT2653465T (xx)
LU (1) LUC00007I2 (xx)
ME (3) ME01601B (xx)
MX (1) MXPA06010642A (xx)
MY (1) MY146972A (xx)
NL (1) NL300865I2 (xx)
NO (3) NO338203B1 (xx)
NZ (1) NZ549842A (xx)
PH (1) PH12012501640A1 (xx)
PL (4) PL2573068T3 (xx)
PT (4) PT2653465T (xx)
RS (4) RS52933B (xx)
SI (4) SI2653465T1 (xx)
TW (1) TWI361069B (xx)
UA (1) UA86053C2 (xx)
WO (1) WO2005090315A1 (xx)
ZA (1) ZA200608587B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
UA86053C2 (ru) 2004-03-15 2009-03-25 Янссен Фармацевтика Н.В. Соединения как модуляторы опиоидных рецепторов
US7244866B2 (en) 2004-05-14 2007-07-17 Janssen Pharmaceutical N.V. Carboxamido opioid compounds
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
CA2601674A1 (en) * 2005-03-14 2006-09-21 Janssen Pharmaceutica N.V. Process for the preparation of opioid modulators
EA014245B1 (ru) * 2005-12-14 2010-10-29 Бристол-Маерс Сквибб Компани Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia
CA2634743C (en) * 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
KR20110122881A (ko) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP2468724B1 (en) * 2006-12-21 2015-11-18 Zealand Pharma A/S Synthesis of pyrrolidine compounds
SG185941A1 (en) * 2007-07-09 2012-12-28 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
JP5536113B2 (ja) 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド がん細胞の転移を予防するための化合物、組成物および方法
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US9447079B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
EP3319444B1 (en) 2015-07-09 2022-03-09 The Regents of the University of California Mu opioid receptor modulators
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
WO2017043626A1 (ja) * 2015-09-11 2017-03-16 株式会社カネカ 光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
CN108290057A (zh) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 用tie-2的激活剂治疗眼内压的方法
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
CN107129444B (zh) * 2016-02-29 2018-08-31 尚科生物医药（上海）有限公司 (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
US20190177282A1 (en) * 2016-05-30 2019-06-13 Sun Pharmaceutical Industries Limited A process for the preparation of eluxadoline
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
WO2018055528A2 (en) * 2016-09-20 2018-03-29 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
WO2018138274A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline forms and processes for their preparation
DK3618847T3 (da) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
CA3109557A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
ES2867895T3 (es) * 2018-11-30 2021-10-21 Phytobiotics Futterzusatzstoffe Gmbh Sistema para el análisis de imágenes de excrementos de animales
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
JP2022530657A (ja) 2019-04-29 2022-06-30 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
WO2021198780A1 (en) 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
AU2021318923A1 (en) * 2020-07-28 2023-03-09 Jazz Pharmaceuticals Ireland Limited Chiral synthesis of fused bicyclic Raf inhibitors
US20220096676A1 (en) 2020-09-29 2022-03-31 Abl Ip Holding Llc Techniques for Directing Ultraviolet Energy Towards a Moving Surface
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
AR003108A1 (es) * 1995-01-27 1998-07-08 Novo Nordisk As Compuestos con propiedades de liberacion de la hormona del crecimiento, composicion farmaceutica que los contienen, el uso de los mismos para la preparación de un medicamento.
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
CA2217006C (en) 1995-04-13 2001-05-22 Hoechst Marion Roussel, Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
CA2203428A1 (en) 1995-08-21 1997-02-27 Philip Arthur Hipskind 2-acylaminopropanamides as growth hormone secretagogues
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
EP1055665B1 (en) * 1999-05-28 2003-10-22 Pfizer Products Inc. 3-(3-Hydroxyphenyl)-3-amino-propionamide derivatives
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
SK6282003A3 (en) 2000-10-30 2004-02-03 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
KR100898562B1 (ko) * 2001-10-15 2009-05-20 얀센 파마슈티카 엔.브이. 신규 치환된 4-페닐-4-[1ｈ-이미다졸-2-일]-피페리딘유도체 및 선택적인 비펩타이드 델타 아편유사작용제로서의 그의 용도
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
UA86053C2 (ru) * 2004-03-15 2009-03-25 Янссен Фармацевтика Н.В. Соединения как модуляторы опиоидных рецепторов
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
CA2601674A1 (en) * 2005-03-14 2006-09-21 Janssen Pharmaceutica N.V. Process for the preparation of opioid modulators

Also Published As

Publication number Publication date
ES2705077T3 (es) 2019-03-21
US20050203143A1 (en) 2005-09-15
RS51995B (en) 2012-04-30
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
ATE516274T1 (de) 2011-07-15
JP4778954B2 (ja) 2011-09-21
US20100324051A1 (en) 2010-12-23
US7786158B2 (en) 2010-08-31
NO2017007I2 (no) 2017-02-23
ME02221B (me) 2016-02-20
EP3112352B1 (en) 2018-11-21
ME02540B (me) 2017-02-20
CY1111927T1 (el) 2015-11-04
HK1155726A1 (en) 2012-05-25
US20140256779A1 (en) 2014-09-11
US10213415B2 (en) 2019-02-26
DK2298744T3 (da) 2013-09-02
HRP20161331T1 (hr) 2016-12-30
EP1725537B1 (en) 2011-07-13
RS54199B1 (en) 2015-12-31
IL178040A (en) 2013-12-31
PL1725537T3 (pl) 2011-12-30
EP2298744A3 (en) 2011-08-10
HK1105967A1 (en) 2008-02-29
NZ549842A (en) 2010-10-29
PH12012501640B1 (en) 2015-10-05
PT1725537E (pt) 2011-09-08
ME01601B (me) 2014-09-20
HRP20150305T1 (hr) 2015-04-24
DK2573068T3 (en) 2015-02-16
IL178040A0 (en) 2006-12-31
WO2005090315A1 (en) 2005-09-29
NO20160916A1 (no) 2006-12-14
PL2653465T3 (pl) 2017-01-31
BRPI0508820B1 (pt) 2018-04-10
ZA200608587B (en) 2008-06-25
ES2596434T3 (es) 2017-01-09
EP1725537A1 (en) 2006-11-29
LUC00007I2 (xx) 2017-05-02
SI2298744T1 (sl) 2013-10-30
DK3112352T3 (en) 2019-01-28
CY2017008I2 (el) 2017-11-14
CR8655A (es) 2008-09-09
US8609709B2 (en) 2013-12-17
CA2560047A1 (en) 2005-09-29
CY1118096T1 (el) 2017-06-28
HUS1700010I1 (hu) 2017-03-28
SI2653465T1 (sl) 2016-10-28
PT2573068E (pt) 2015-04-27
HK1184432A1 (en) 2014-01-24
IL229444A0 (en) 2013-12-31
RS52933B (en) 2014-02-28
BRPI0508820B8 (pt) 2022-11-29
US20180325870A1 (en) 2018-11-15
MXPA06010642A (es) 2007-03-26
CN1950342B (zh) 2012-09-26
SI1725537T1 (sl) 2011-11-30
CA2560047C (en) 2013-12-24
CY2017008I1 (el) 2017-11-14
AU2005224091B2 (en) 2012-02-02
IL229444A (en) 2017-03-30
JP2007529527A (ja) 2007-10-25
ES2533176T3 (es) 2015-04-08
EP2298744B1 (en) 2013-06-26
NO20064660L (no) 2006-12-14
EP3112352A1 (en) 2017-01-04
EP2298744A2 (en) 2011-03-23
US9205076B2 (en) 2015-12-08
NO338203B1 (no) 2016-08-08
AR048269A1 (es) 2006-04-12
US20130090478A1 (en) 2013-04-11
RS55122B1 (sr) 2016-12-30
UA86053C2 (ru) 2009-03-25
ES2428008T3 (es) 2013-11-05
PL2573068T3 (pl) 2015-06-30
ES2367576T3 (es) 2011-11-04
CN102786476A (zh) 2012-11-21
MY146972A (en) 2012-10-15
NL300865I1 (nl) 2017-03-14
US8344011B2 (en) 2013-01-01
EP2573068A1 (en) 2013-03-27
US20160030393A1 (en) 2016-02-04
CN1950342A (zh) 2007-04-18
US20140039024A1 (en) 2014-02-06
HUE029852T2 (en) 2017-04-28
HRP20110694T1 (hr) 2011-12-31
IL224908A (en) 2015-07-30
LTPA2017005I1 (lt) 2017-03-27
LTC1725537I2 (lt) 2018-02-26
EP2653465B1 (en) 2016-07-13
LT2653465T (lt) 2016-09-12
US9700542B2 (en) 2017-07-11
AU2005224091A1 (en) 2005-09-29
DK2653465T3 (da) 2016-08-22
PT2298744E (pt) 2013-09-12
DK1725537T3 (da) 2011-10-31
KR101166342B1 (ko) 2012-07-18
HRP20130800T1 (xx) 2013-09-30
LUC00007I1 (xx) 2017-03-03
PT2653465T (pt) 2016-09-22
BRPI0508820A (pt) 2007-08-07
TW200539876A (en) 2005-12-16
CN102786476B (zh) 2017-01-18
US8772325B2 (en) 2014-07-08
EP2573068B9 (en) 2015-08-26
AR095848A2 (es) 2015-11-18
EP2573068B1 (en) 2014-12-31
PL2298744T3 (pl) 2013-11-29
KR20060131983A (ko) 2006-12-20
NL300865I2 (nl) 2020-08-17
EP2653465A1 (en) 2013-10-23
NO2017007I1 (no) 2017-02-23
US7741356B2 (en) 2010-06-22
ECSP066856A (es) 2006-11-24
SI2573068T1 (sl) 2015-03-31
PH12012501640A1 (en) 2015-10-05

Similar Documents

Publication Publication Date Title
HK1099016A1 (en) Novel compounds as opioid receptor modulators
HU0400405D0 (en) Novel compounds
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
HK1159064A1 (en) Processes for the preparation of aminosulfone compounds
TW200503724A (en) Novel pharmaceuticals
MX2009000475A (es) Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
EA200701588A1 (ru) Способы получения замещённых фенилпиразолмочевин
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
HK1080088A1 (zh) 製備c-7取代的5-雄甾烯的方法
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
RS20080119A (xx) Derivati karboksamida kao antagonisti receptora muskarina
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
MX2007007720A (es) Derivados de pirrolidinio como receptores m3 muscarinicos.
UA101482C2 (ru) Способ получения 2'-дезокси-5-азацитидина (децитабина)
WO2007082262A3 (en) Novel compounds
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
SI1723140T1 (sl) Postopek za pripravo inhibitorjev triptaze
TW200640870A (en) Novel compounds
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
TW200616624A (en) 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity
GB0320738D0 (en) Novel process
SG155231A1 (en) Process for synthesis of dialkoxyorganoboranes

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230314